Showing posts with label XL184; marketed under the trade name Cometriq). Show all posts
Showing posts with label XL184; marketed under the trade name Cometriq). Show all posts
Tuesday, October 13, 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

›
In continuation of my update on cabozantinib Patients with advanced kidney cancer live for nearly twice as long without their dise...